Diagnosis, Diagnostics, Immunodiagnosis & Immunodiagnostics:

9824.   Acosta-Rivero N, Duenas-Carrera S, Alvarez-Lajonchere L, Morales- Grillo J. HCV core protein-expressing DNA vaccine induces a strong class I-binding peptide DTH response in mice. Biochem Biophys Res Commun. 2004 Feb 13;314(3):781-6.

9825.   Amoroso P, Buonocore S, Lettieri G, Pierri P, Mele A. The clinical profile of acute hepatitis A infection: is it really so severe? Hepatology. 2004 Feb;39(2):572; author reply 572-3.

9826.   Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology. 2004 Feb;39(2):273-8. Review.

9827.   Cao Y, Hamada T, Matsui T, Date T, Iwabuchi K. Hepatitis C virus core protein interacts with p53-binding protein, 53BP2/Bbp/ASPP2, and inhibits p53-mediated apoptosis. Biochem Biophys Res Commun. 2004 Mar 19;315(4):788-95.

9828.   Chau TN, Lee KC, Yao H, Tsang TY, Chow TC, Yeung YC, Choi KW, Tso YK, Lau T, Lai ST, Lai CL. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology. 2004 Feb;39(2):302-10.

9829.   Chen Y, Sze J, He ML. HBV cccDNA in patients' sera as an indicator for HBV reactivation and an early signal of liver damage. World J Gastroenterol. 2004 Jan;10(1):82-5.

9830.   Dai CY, YuML, Chen SC, Lin ZY, Hsieh MY, Wang LY, Tsai JF, Chuang WL, Chang WY. Clinical evaluation of the COBAS Amplicor HBV monitor test for measuring serum HBV DNA and comparison with the Quantiplex branched DNA signal amplification assay in Taiwan. J Clin Pathol. 2004 Feb;57(2):141-5.

9831.   Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother. 2004 Jan;53(1):15-8. Epub 2003 Nov 25. Review. 

9832.   Friedman LS. Controversies in liver biopsy: who, where, when, how, why? Curr Gastroenterol Rep. 2004 Feb;6(1):30-6. Review.

9833.   Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004 Mar 11;350(11):1118-29. Review.

9834.   Grassi A, Susca M, Ferri S, Gabusi E, D'Errico A, Farina G, Maccariello S, Zauli D, Bianchi FB, Ballardini G. Detection of the M30 neoepitope as a new tool to quantify liver apoptosis: timing and patterns of positivity on frozen and paraffin-embedded sections. Am J Clin Pathol. 2004 Feb;121(2):211-9. 

9835.   Ismail N, Fish GE, Smith MB. Laboratory evaluation of a fully automated chemiluminescence immunoassay for rapid detection of HBsAg, antibodies to HBsAg, and antibodies to hepatitis C virus. J Clin Microbiol. 2004 Feb;42(2):610-7. 

9836.   Kiely P, Kay D, Parker S, Piscitelli L. The significance of third-generation HCV RIBA-indeterminate, RNA-negative results in voluntary blood donors screened with sequential third-generation immunoassays. Transfusion. 2004 Mar;44(3):349-58.

9837.   Lerat H, Hollinger FB. Hepatitis C virus (HCV) occult infection or occult HCV RNA detection? J Infect Dis. 2004 Jan 1;189(1):3-6. Epub 2003 Dec 31. Review.

9838.   Lin KW, Kirchner JT. Hepatitis B. Am Fam Physician. 2004 Jan 1;69(1):75-82. Review. 

9839.   Rajesh K, Bhoi S, Manish K, Sharma B, Singh BM, Gupta BB. Guillain-Barre syndrome and acute hepatitis E: a rare association. J Indian Acad Clin Med 2002; 3(4): 389-91.

9840.   Raker CA, Tabor E, Okayama A, Yu MY, Kohara M, Mueller NE, Tsubouchi H, Stuver SO. HCV core antigen as an alternative to NAT to detect HCV viremia. Transfusion. 2004 Feb;44(2):307-8.

9841.   Ratziu V, Trabut JB, Poynard T. Fat, diabetes, and liver injury in chronic hepatitis C. Curr Gastroenterol Rep. 2004 Feb;6(1):22-9. Review. 

9842.   Rocholl C, Gerber K, Daly J, Pavia AT, Byington CL. Adenoviral infections in children: the impact of rapid diagnosis. Pediatrics. 2004 Jan;113(1 Pt 1):e51-6. 

9843.   Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC; Trent Hepatitis C Study Group. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004 Mar;53(3):451-5.

9844.   Sansonno D, Lauletta G, Dammacco F. Detection and quantitation of HCV core protein in single hepatocytes by means of laser capture microdissection and enzyme-linked immunosorbent assay. J Viral Hepat. 2004 Jan;11(1):27-32. 

9845.   Talal AH, Shata MT, Markatou M, Dorante G, Chadburn A, Koch R, Neumann AU, Ribeiro RM, Perelson AS. Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV. J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):103-13. 

9846.   van der Eijk AA, Niesters HG, Gotz HM, Janssen HL, Schalm SW, Osterhaus AD, de Man RA. Paired measurements of quantitative hepatitis B virus DNA in saliva and serum of chronic hepatitis B patients: implications for saliva as infectious agent. J Clin Virol. 2004 Feb;29(2):92-4.

9847.   Verucchi G, Calza L, Manfredi R, Chiodo F. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. Infection. 2004 Feb;32(1):33-46. Review. 

9848.   Ward RP, Kugelmas M, Libsch KD. Management of hepatitis C: evaluating suitability for drug therapy. Am Fam Physician. 2004 Mar 15;69(6):1429-36. Review. 

9849.   Yao JD, Beld MG, Oon LL, Sherlock CH, Germer J, Menting S, Se Thoe SY, Merrick L, Ziermann R, Surtihadi J, Hnatyszyn HJ. Multicenter evaluation of the VERSANT hepatitis B virus DNA 3.0 assay. J Clin Microbiol. 2004 Feb;42(2):800-6. 

9850.   Zafrani ES. Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Arch. 2004 Jan;444(1):3-12. 

Pathogenesis:

9851.   Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells.  Gastroenterology. 2004 Feb;126(2):529-40.

9852.   Brenner DA. Gastrointestinal basic science 2002-2003: the year in review. Clin Gastroenterol Hepatol. 2004 Jan;2(1):9-13. Review.

9853.   Chen HL, Chang CJ, Kong MS, Huang FC, Lee HC, Lin CC, Liu CC, Lee IH, Wu TC, Wu SF, Ni YH, Hsu HY, Chen DS, Chang MH. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology. 2004 Jan;39(1):58-63.

9854.   Ciancio A, Smedile A, Rizzetto M, Lagget M, Gerin J, Korba B. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy. Hepatology. 2004 Jan;39(1):64-73.

9855.   Collantes RS, Younossi ZM. How great is the risk of transmitting the hepatitis C virus sexually? Cleve Clin J Med. 2004 Feb;71(2):160-1.

9856.   D'Abramo CM, Cellai L, Gotte M. Excision of incorporated nucleotide analogue chain-terminators can diminish their inhibitory effects on viral RNA-dependent RNA polymerases. J Mol Biol. 2004 Mar 12;337(1):1-14.

9857.   Daiba A, Inaba N, Ando S, Kajiyama N, Yatsuhashi H, Terasaki H, Ito A, Ogasawara M, Abe A, Yoshioka J, Hayashida K, Kaneko S, Kohara M, Ito S. A low-density cDNA microarray with a unique reference RNA: pattern recognition analysis for IFN efficacy prediction to HCV as a model. Biochem Biophys Res Commun. 2004 Mar 19;315(4):1088-96.

9858.   Fiore AE. Hepatitis A transmitted by food. Clin Infect Dis. 2004 Mar 1;38(5):705-15.

9859.   Francavilla V, Accapezzato D, De Salvo M, Rawson P, Cosimi O, Lipp M, Cerino A, Cividini A, Mondelli MU, Barnaba V. Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: exploring the immunological mechanisms. Eur J Immunol. 2004 Feb;34(2):427-37.

9860.   Goyal A, Kazim SN, Sakhuja P, Malhotra V, Arora N, Sarin SK. Association of TNF-beta polymorphism with disease severity among patients infected with hepatitis C virus. J Med Virol. 2004 Jan;72(1):60-5. Erratum in: J Med Virol. 2004 Mar;72(3):509.

9861.   Gremion C, Grabscheid B, Wolk B, Moradpour D, Reichen J, Pichler W, Cerny A. Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. J Virol. 2004 Feb;78(4):2152-7.

9862.   Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS. 2004 Jan;15(1):7-16.

9863.   Hsu SC, Wu JC, Sheen IJ, Syu WJ. Interaction and replication activation of genotype I and II hepatitis delta antigens. J Virol. 2004 Mar;78(6):2693-700.

9864.   Lopez-Vazquez A, Rodrigo L, Mina-Blanco A, Martinez-Borra J, Fuentes D, Rodriguez M, Perez R, Gonzalez S, Lopez-Larrea C. Extended human leukocyte antigen haplotype EH18.1 influences progression to hepatocellular carcinoma in patients with hepatitis C virus infection. J Infect Dis. 2004 Mar 15;189(6):957-63.

9865.   Mu JJ, Tsay YG, Juan LJ, Fu TF, Huang WH, Chen DS, Chen PJ. The small delta antigen of hepatitis delta virus is an acetylated protein and acetylation of lysine 72 may influence its cellular localization and viral RNA synthesis. Virology. 2004 Feb 5;319(1):60-70.

9866.   Murakami Y, Minami M, Daimon Y, Okanoue T. Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen. J Med Virol. 2004 Feb;72(2):203-14.

9867.   Naganuma A, Dansako H, Nakamura T, Nozaki A, Kato N.  Promotion of microsatellite instability by hepatitis C virus core protein in human non-neoplastic hepatocyte cells. Cancer Res. 2004 Feb 15;64(4):1307-14.

9868.   Nagao Y, Tanaka K, Kobayashi K, Kumashiro R, Sata M. A cohort study of chronic liver disease in an HCV hyperendemic area of Japan: a prospective analysis for 12 years. Int J Mol Med. 2004 Feb;13(2):257-65.

9869.   Op De Beeck A, Voisset C, Bartosch B, Ciczora Y, Cocquerel L, Keck Z, Foung S, Cosset FL, Dubuisson J. Characterization of functional hepatitis C virus envelope glycoproteins. J Virol. 2004 Mar;78(6):2994-3002.

9870.   Pan J, Clayton M, Feitelson MA. Hepatitis B virus X antigen promotes transforming growth factor-beta1 (TGF-beta1) activity by up-regulation of TGF-beta1 and down-regulation of alpha2-macroglobulin. J Gen Virol. 2004 Feb;85(Pt 2):275-82.

9871.   Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Crax A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004 Jan;126(1):102-10.

9872.   Romero-Gomez M, Montes-Cano MA, Otero-Fernandez MA, Torres B, Sanchez-Munoz D, Aguilar F, Barroso N, Gomez-Izquierdo L, Castellano-Megias VM, Nunez-Roldan A, Aguilar-Reina J, Gonzalez-Escribano MF. SLC11A1 promoter gene polymorphisms and fibrosis progression in chronic hepatitis C. Gut. 2004 Mar;53(3):446-50.

9873.   Scholle F, Li K, Bodola F, Ikeda M, Luxon BA, Lemon SM. Virus-host cell interactions during hepatitis C virus RNA replication: impact of polyprotein expression on the cellular transcriptome and cell cycle association with viral RNA synthesis. J Virol. 2004 Feb;78(3):1513-24.

9874.   Schwartz J, Harrison E, Anderson M, Byrne T, Vargas HE, Douglas DD, Rakela J. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors? Dig Dis Sci. 2004 Jan;49(1):25-9.

9875.   Siavoshian S, Abraham JD, Kieny MP, Schuster C. HCV core, NS3, NS5A and NS5B proteins modulate cell proliferation independently from p53 expression in hepatocarcinoma cell lines. Arch Virol. 2004 Feb;149(2):323-36.

9876.   Tanaka T, Inoue K, Hayashi Y, Abe A, Tsukiyama-Kohara K, Nuriya H, Aoki Y, Kawaguchi R, Kubota K, Yoshiba M, Koike M, Tanaka S, Kohara M. Virological significance of low-level hepatitis B virus infection in patients with hepatitis C virus associated liver disease. J Med Virol. 2004 Feb;72(2):223-9.

9877.   Thelu MA, Drouet E, Hilleret MN, Zarski JP. Lack of clinical significance of variability in the internal ribosome entry site of hepatitis C virus. J Med Virol. 2004 Mar;72(3):396-405.

9878.   Weinman SA, Belalcazar LM. Hepatitis C: a metabolic liver disease. Gastroenterology. 2004 Mar;126(3):917-9. Review.

9879.   Wheeler JM, Mortensen NJ. Patient to surgeon infections--fact or fiction (Br J Surg 2003; 90: 1315-1316). Br J Surg. 2004 Feb;91(2):253.

9880.   You S, Stump DD, Branch AD, Rice CM. A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. J Virol. 2004 Feb;78(3):1352-66.

9881.   Zhang SL, Yue YF, Bai GQ, Shi L, Jiang H. Mechanism of intrauterine infection of hepatitis B virus. World J Gastroenterol. 2004 Feb 1;10(3):437-8.

Vaccines:

9882.   De Schryver A, De Gendt K, Francois G, Van Damme P, Meheus A. Hepatitis B surface antigenaemia following vaccination with a combined vaccine against hepatitis A and B. J Viral Hepat. 2004 Jan;11(1):88-90.

9883.   Puliyel JM. Plea to restore public funding for vaccine development. Lancet. 2004 Feb 21;363(9409):659.

9884.   Torresi J, Bharadwaj M, Jackson DC, Gowans EJ. Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy. Curr Drug Targets. 2004 Jan;5(1):41-56. Review.

9885. Wang RX, Guo Y, Yang CH, Song Y, Chen J, Pang FS, Lei SP, Jia XM, Wen JY, Shi CY. Can HB vaccine yield a booster effect on individuals with positive serum anti-HBs and anti-HBc markers? World J Gastroenterol. 2004 Jan 15;10(2):306-8.

Therapy:

9886.   Andreone P, Gramenzi A, Cursaro C, Felline F, Loggi E, D'Errico A, Spinosa M, Lorenzini S, Biselli M, Bernardi M. Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial. J Viral Hepat. 2004 Jan;11(1):69-73.

9887.   Angelico M, Cepparulo M, Angelico F, Francioso S, Barlattani A, Di Candilo F, Della Vecchia R, Demelia L, De Sanctis G, Gentile S, Grieco A, Parruti G, Sabusco G, Tarquini L, Tosti A, Zaru S; THE SMIEC 1 GROUP.  A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomised according to the early virological response to interferon-alpha2a monotherapy. Aliment Pharmacol Ther. 2004 Feb 1;19(3):339-47. 

9888.   Dev A, Patel K, McHutchison JG. New therapies for chronic hepatitis C virus infection. Curr Gastroenterol Rep. 2004 Feb;6(1):77-86. Review. 

9889.   Guardiola P. Effect of HAART on liver-related mortality in patients with HIV/HCV coinfection. Lancet. 2004 Feb 14;363(9408):570; author reply 571.

9890.   Khokhar N. Treatment of interferon non-responsive chronic hepatitis C with triple therapy with interferon, ribavirin, and amantidine can be encouraging. Gut. 2004 Mar;53(3):468-9.

9891.   Klebl BM. Stacking up the armory against viruses. Drug Discov Today. 2004 Feb 15;9(4):162-4.

9892.   Raney AK, Hamatake RK, Hong Z. HEP DART 2003: Frontiers in drug development for viral hepatitis. Expert Opin Investig Drugs. 2004 Mar;13(3):289-93. 

9893.   Russo MW, Fried MW. Guidelines for stopping therapy in chronic hepatitis C. Curr Gastroenterol Rep. 2004 Feb;6(1):17-21. Review.

9894.   Thio CL. Management of chronic hepatitis B in the HIV-infected patient. AIDS Read. 2004 Mar;14(3):122-9, 133, 136-7. Review.

9895. Zollner B, Petersen J, Puchhammer-Stockl E, Kletzmayr J, Sterneck M, Fischer L, Schroter M, Laufs R, Feucht HH. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology. 2004 Jan;39(1):42-50.